The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution*

The structure of P450 3A4 was determined by x-ray crystallography to 2.05-Å resolution. P450 3A4 catalyzes the metabolic clearance of a large number of clinically used drugs, and a number of adverse drug-drug interactions reflect the inhibition or induction of the enzyme. P450 3A4 exhibits a relatively large substrate-binding cavity that is consistent with its capacity to oxidize bulky substrates such as cyclosporin, statins, taxanes, and macrolide antibiotics. Family 3A P450s also exhibit unusual kinetic characteristics that suggest simultaneous occupancy by smaller substrates. Although the active site volume is similar to that of P450 2C8 (PDB code: 1PQ2), the shape of the active site cavity differs considerably due to differences in the folding and packing of portions of the protein that form the cavity. Compared with P450 2C8, the active site cavity of 3A4 is much larger near the heme iron. The lower constraints on the motions of small substrates near the site of oxygen activation may diminish the efficiency of substrate oxidation, which may, in turn, be improved by space restrictions imposed by the presence of a second substrate molecule. The structure of P450 3A4 should facilitate a better understanding of the substrate selectivity of the enzyme.

[1]  G. Wilkinson Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of pharmacokinetics and biopharmaceutics.

[2]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[3]  Eric F. Johnson,et al.  Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å Resolution , 2004, Journal of Biological Chemistry.

[4]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[5]  James R. Halpert,et al.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[7]  C David Stout,et al.  Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.

[8]  C David Stout,et al.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.

[9]  M. J. Coon,et al.  Kinetic isotope effects implicate two electrophilic oxidants in cytochrome p450-catalyzed hydroxylations. , 2003, Journal of the American Chemical Society.

[10]  J. Halpert,et al.  Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.

[11]  Sam-Yong Park,et al.  Crystallization and preliminary X-ray diffraction analysis of fatty-acid hydroxylase cytochrome P450BSβ from Bacillus subtilis , 2002 .

[12]  C. Wolf,et al.  CYP3A4 active site volume modification by mutagenesis of leucine 211. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[13]  P. Ortiz de Montellano,et al.  Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. , 2002, Biochemistry.

[14]  Eric F. Johnson,et al.  Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. , 2002, Methods in enzymology.

[15]  J. Halpert,et al.  Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.

[16]  J. Halpert,et al.  Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  M. Sutcliffe,et al.  Amino acid 305 determines catalytic center accessibility in CYP3A4. , 2000, Biochemistry.

[18]  J Berendzen,et al.  The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.

[19]  J. Halpert,et al.  The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. , 2000, Archives of biochemistry and biophysics.

[20]  Eric F. Johnson,et al.  Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme , 2000, The Journal of Biological Chemistry.

[21]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[22]  E. Tanaka,et al.  Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.

[23]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[24]  T. Richardson,et al.  Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. , 1998, Biochemistry.

[25]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[26]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[28]  James R. Halpert,et al.  Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.

[29]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[30]  A. Li,et al.  Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.

[31]  S. Wrighton,et al.  Interactions of peroxyquinols with cytochromes P450 2B1, 3A1, and 3A5: influence of the apoprotein on heterolytic versus homolytic O-O bond cleavage. , 1995, Archives of biochemistry and biophysics.

[32]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[33]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[34]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[35]  S. Sligar,et al.  A role for Asp-251 in cytochrome P-450cam oxygen activation. , 1994, The Journal of biological chemistry.

[36]  E. Johnson,et al.  Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. , 1988, The Journal of biological chemistry.

[37]  C. Jefcoate,et al.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. , 1978, Methods in enzymology.